Çocukluk Çağı Başağrılarında Güncel ve Gelecek Tedaviler

Puledda F, Sacco S, Diener HC, et al. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia. 2024;44(8):3331024241252666.

Sculpher M, Millson D, Meddis D, et al. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study. PharmacoEconomics. 2002;20:91-100.

Ashina S, Terwindt GM, Steiner TJ, et al. Medication overuse headache. Nat Rev Dis Primers. 2023;9:5.

Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19-26.

Cady RK, Lipton RB, Hall C, et al. Treatment of mild headache in disabled migraine sufferers: Results of the spectrum study. Headache. 2000; 40:792-797.

Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633-658.

Olesen J, Diener HC, Schoenen J, et al. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol. 2004;11:671-677.

Burstein R, Jakubowski M. Managing migraine associated with sensitization. Handb Clin Neurol. 2010;97:207-215.

Vandenbussche N, Laterza D, Lisicki M, et al. Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain. 2018;19:50.

Diener HC, Dodick D, Evers S, et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 2019;18:891-902.

American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1-18.

Rapoport AM, Bigal ME, Tepper SJ, et al. Intranasal medications for the treatment of migraine and cluster headache. CNS Drugs. 2004;18:671-685.

Boureau F, Kappos L, Schoenen J, et al. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin. 2000;54:281-286.

Croop R, Madonia J, Stock DA, et al. Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose ranging trial. Headache. 2022;62:1153-1163.

Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;2012:CD009665.

Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003;43:144-166.

Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021;397:1505-1518.

Hakkarainen H, Vapaatalo H, Gothoni G, et al. Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet. 1979;314:326-328.

Kangasniemi P, Kaaja RJ. Ketoprofen and ergotamine in acute migraine. J Intern Med. 1992;231:551-554.

Meyler W. Side effects of ergotamine. Cephalalgia. 1996;16:5-10.

Vaz JM, Alves BM, Duarte DB, et al. Quality appraisal of existing guidelines for the management of headache disorders by the AGREE II’s method. Cephalalgia. 2022;42:239-249.

Li D, Abreu J, Tepper SJ. A brief review of gepants. Curr Pain Headache Rep. 2023;27:479-488.

Puledda F, Younis S, Huessler E-M, et al. Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature. Cephalalgia. 2023;43:3331024231151419.

Ailani J, Lipton RB, Hutchinson S, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache. 2020;60:141-152.

Johnston K, Harris L, Powell L, et al. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201). J Headache Pain. 2022;23:10.

Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22:209-217.

Jones J, Pack S, Chun E. Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache. Am J Emerg Med. 1996;14:262-264.

Golikhatir I, Cheraghmakani H, Bozorgi F, et al. The efficacy and safety of prochlorperazine in patients with acute migraine: a systematic review and meta-analysis. Headache. 2019;59:682-700.

Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol. 2009;16:968-981.

Reiter PD, Nickisch J, Merritt G. Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine. Headache. 2005;45(7):899-903.

Avraham SB, Har-Gil M, Watemberg N. Acute confusional migraine in an adolescent: response to intravenous valproate. Pediatrics. 2010;125(4):e956-959.

Schwedt TJ, Alam A, Reed ML, et al. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain. 2018;19:1-9.

Lipton RB, Serrano D, Nicholson RA, et al. Impact of NSAID and Triptan use on developing chronic migraine: results from the a merican migraine prevalence and prevention (AMPP) study. Headache. 2013;53:1548-1563.

Puledda F, Sacco S, Diener HC, et al. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine. Cephalalgia. 2024;44(9):1-31.

Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:51-60.

Ailani J, McAllister P, Winner PK, et al. Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial. BMC Neurology. 2022;22:205.

Silberstein SD, Dodick DW, Lindblad AS, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology. 2012;78:976-984.

Shamliyan TA, Kane RL, Taylor FR. Migraine in adults: preventive pharmacologic treatments. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ), 2013. https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/migraine-prevention_research-2013.pdf.

Pascual J, Leira R, Láinez JM. Combined therapy for migraine prevention? Clinical experience with a betablocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia. 2003;23:961-962.

Cohen F, Armand C, Lipton RB, et al. Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to OnabotulinumtoxinA in patients with chronic migraine. Pain Med. 2021;22:1857-1863.

Al-Hassany L, Lyons HS, Boucherie DM, et al. The sense of stopping migraine prophylaxis. J Headache Pain. 2023;24:9-9.

Raffaelli B, Terhart M, Mecklenburg J, et al. Resumption of migraine preventive treatment with CGRP (-receptor) antibodies after a 3-month drug holiday: a real-world experience. J Headache Pain. 2022;23:1-8.

Stubberud A, Flaaen NM, McCrory DC, et al. Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis. Pain. 2019;160:762-772.

Powers SW, Coffey CS, Chamberlin LA, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017;376:115-124.

Kohandel Gargari O, Aghajanian S, Togha M, et al. Preventive Medications in Pediatric Migraine: A Network Meta-Analysis. JAMA Netw Open. 2024;7(10):e2438666.

Locher C, Kossowsky J, Koechlin H, et al. Efficacy, Safety, and Acceptability of Pharmacologic Treatments for Pediatric Migraine Prophylaxis: A Systematic Review and Network Meta-analysis. JAMA Pediatr. 2020;174(4):341.

Lewis DW, Diamond S, Scott D, Jones V. Prophylactic treatment of pediatric migraine. Headache. 2004;44(3):230.

Locher C, Kossowsky J, Koechlin H, et al. Efficacy, safety, and acceptability of pharmacologic treatments for pediatric migraine prophylaxis: a systematic review and network meta-analysis. JAMA Pediatr. 2020;174:341-349.

Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: pharmacologic treatment for pediatric migraine prevention: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019;93:500-509.

Ashrafi MR, Salehi S, Malamiri RA, et al. Efficacy and safety of cinnarizine in the prophylaxis of migraine in children: a double-blind placebo-controlled randomized trial. Pediatr Neurol. 2014;51(4):503-8.

Amanat M, Togha M, Agah E, et al. Cinnarizine and sodium valproate as the preventive agents of pediatric migraine: A randomized double-blind placebo-controlled trial. Cephalalgia. 2020;40(7):665.

Sorge F, De Simone R, Marano E, Nolano M, Orefice G, Carrieri P. Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study. Cephalalgia. 1988;8(1):1.

Stubberud A, Flaaen NM, McCrory DC, Pedersen SA, Linde M. Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis. Pain. 2019;160(4):762.

Apostol G, Cady RK, Laforet GA, et al. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. Headache. 2008;48(7):1012-1025.

Powers SW, Coffey CS, Chamberlin LA, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017;376:115-124.

Hershey AD, Powers SW, Bentti AL, et al. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. Headache. 2000;40:539-549.

Hershey AD, Powers SW, Bentti AL, Degrauw TJ. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. Headache. 2000;40(7):539.

Rajapakse T, Gantenbein AR. Nutraceuticals in migraine. Handbook of Clinical Neurology. 2024;199:125-144.

Tepper SJ, Tepper K. Nutraceuticals and headache 2024: Riboflavin, coenzyme Q10, feverfew, magnesiun, melatonin, and butterbur. Curr Pain Headache R. 2025;29:33.

MacLennan SC, Wade FM, Forrest KM, Ratanayake PD, Fagan E, Antony J. High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol. 2018;23:1300-1304.

Bruijn J, Duivenvoorden H, Passchier J, Locher H, Dijkstra N, Arts WF. Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomized, double-blind, cross-over trial. Cephalalgia. 2010;30:1426-1434.

Martello E, Aiyelabegan F, Orr J, et al. Systematic review suggests nutraceuticals containing B2 could provide an alternative treatment for pediatric migraines. Acta Pediatrica. 2025;114:2443-2457.

Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: Report of the Quality standarts Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1346-1353.

Medrea I, Cooper P, Lamgman M, et al. Updated Canadian Headache Society Migraine Prevention Guideline with Systematic Review, and Metanalysis. Can J Neurol Sci. 2024;7:1-23.

Vegh K, Riethmüller E, Hosszu L, et al. Three newly identified lipophilic flavanoids in Tanacetum parthenium süper-critical fluid extract penetrating the blood-brain barrier. J Pharm Biomed Anal. 2018;149:488-493.

Recinella L, Chivaroli A, di Giacomo V, et al. Anti-inflammatory and neuromodulatory effects induced vt Tanacetum parthenium water extract: results from in silico, in vitro and ex vivo studies. Molecules. 2021;26:22.

Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res Ed.) 1985;291(6495):569-73.

Kulinowski L, Luca SV, Minceva M, Skalicka-Wozniak K. A review on the ethnobotany, phytochemistry, pharmacology and toxicology of butterber species Petasites L). J Ethnopharmacol. 2022;293:115263.

Borlak J, Diener HC, Kleeberg-Hartmann J, Messlinger K, Silberstein S. Petasites for migraine prevention: New data on mode of action, pharmacology and sfety. A narrative review. Front Neurol. 2022;13:864689.

Domitrz I, Cegielska J. Magnesium as an important factor in the pathogenesis and treatment of migraine- from theory to practice. Nutrients. 2022;14:1089.

Myrdal U, Leppert J, Edvinsson L, et al. Magnesium sulphate infusion decreases circulating calcitonin gene-related peptide (CGRP) in women with primary Raynould’s phenomenon. Clin Physiol. 1994;14(5):539-546.

Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(Suppl 2):S1-59).

Leone M, Lucini V, D’Amico D, et al. Twenty four-hour melatonin and cortisol plasma levels in relation to timing of cluster headache. Cephalalgia. 1995;15:224-229.

Gelfand AA, Qubty W, Patniyot I, et al. Home-Based Trials in Adolescent Migraine: A Randomized Clinical Trial. JAMA Neurol. 2017;74(6):744.

Ramsden CE, Faurot KR, Zamora D, et al. Targeted alteration on dietary n-3 and n-6 fatty acids fort he treatment of chronic headaches: a randomized trial. Pain.2013;154:2441-2451.

Mann JD, Faurot KR, MacIntosh B, et al. A sixteen-week three-armed, randomized, controlled trial investigating clinical and biochemical effects of targeted alterations in dietary linoleic acid and n-3 EPA+DHA in adults with episodic migraine: study protocol. Prostaglandins Leukot Essent Fatty Acids. 2018;128:41-52.

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1.

Orr SL. Headache in Children and Adolescents. Continuum (Minneap Minn). 2024;30(2):438.

Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013;80(8):697-704.

Schoenen JE. Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial. Neurology. 2016;86:201-202.

Rusto A, Tessitore A, Conte F, Marcuccio F, Giordano A, Tedeschi G. Noninvasive vagus nerve stimulation as acute therapy for migraiene: The randomized PRESTO study. Neurology. 2018;91:e364-e373.

Silberstein SD, Calhoun AH, Lipton RB, et al., EVENT Study Group. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT Study. Neurology. 2026;87:529-538.

Gazerani P. Episodic migraine in the pediatric population: Behavioral therapies and other non-pharmacological treatment options. Curr Pain Headache R. 2025;29:57.

Lloyd JO, Hill B, Murphy M, Al-Kaisy A, Andreou AP, Lambru G. Single-pulse transcranial magnetic stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis. J Headache Pain. 2022;23(1):63.

Miller RN, Kim ME, Gündüz MT, Alyward SC. Advancements in pediatric headache. Curr Opin Pediatr. 2024;36:624-629.

Monteith TS, Stark-Inbar A, Shmuely S, et al. Remote electrical neuromodulation (REN) wearable device for adolescents with migraine: a real-world study of high-frequency abortive treatment suggests preventive effects. Front Pain Res (Lausanne). 2023;4:1247313.

Esparham A, Stark-Inbar A, Jekel L, et al. Acute treatment of migraine in adolescents: real-world analysis of remote electrical neuromodulation (REN). Pediatr Neurol. 2023;142:51-55.

Kemp WJ, Tubbs RS, Cohen-Gadol AA. The innervation of the scalp: a comprehensive review including anatomy, pathology, and neurosurgical correlates. Surg Neurol Int. 2011;2:178.

Morozova M, MacLeod S, Carragher R, Abu-Arafeh I. Greater occipital nerve block for chronic headache management in children and adolescents: A longitudinal observational study and systemic review. Headache. 2025;65:1754-1765.

Chowdhury D, Mundra A. Role of greater occipital nerve block for preventive treatment of chronic migraine: a critical review. Cephalalgia Rep. 2020;3:1-20.

Miller RN, Kim ME, Gündüz MT, Alyward SC. Advancements in pediatric headache. Curr Opin Pediatr. 2024;36:624-629.

Lv X, Wu Z, Li Y. Innervation of the cerebral dura mater. Neuroradiol J. 2014;27:293-298.

Fontaine D, Almairac F, Santucci S, et al. Dural and pial pain-sensitive structures in humans: New inputs from awake craiotomies. Brain. 2018;141:1040-1048.

Boyett D, Khoury NM, Shlobin N, Yugrakh MS, Lavine S, Mandigo GK. Middle meningeal artery embolization for migraine: A review. Surg Neurol Int. 2025;16:475.

Gal L, Michel JF, Rinaldi VE, et al. Association between functional gastrointestinal disordersand migraine in children and adolescents: a case-control study. Lancet Gastroenterol Hepatol. 2016;1(2):114-121.

Fan P, Chua H, Lin C, et al. targeting the microbiome in pediatric migraine: gastrointestinal manifestations and the therapeutic role of Bifidobacterium longum. Gut Microbes. 2026;18:2606487.

AAN Clinical Trials Plenary Session: SPACE study (April 7, 2025) https://www.neurology.org/doi/10.1212/WNL.0000000000211143).

Bandatmakur ASM, Dave P, Kerr M, Brunick C, Wen S, Hansen N. Effectiveness and Tolerability of Anti-Calcitonin Gene-Related Peptide Therapy for Migraine and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA. Brain Sci. 2024;14(9):879.

Greene KA, Gentile CP, Szperka CL, Yonker M, Gelfand AA, Grimes B, Irwin SL. Calcitonin Gene-Related Peptide Monoclonal Antibody Use for the Preventive Treatment of Refractory Headache Disorders in Adolescents. Pediatr Neurol. 2021;114:62.

Sacco S, Braschinsky M, Ducros A, et al. European headache federation consensus on the definition of resistant and refractory migraine : Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020;21(1):76.

Dodick DW, Turkel CC, DeGryse RE, et al.; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921-936.

Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373.

Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack AA. Long-term of the efficacy and safety of OnabotulinumtoxinA fort he prevention of chronic migraine: COMPEL Study. J Headache Pain. 2018;19(1):13.

Lindsay R, Kalifa A, Kuziek J, Kabbouche M, Hershey AD, Orr SL. The safety and efficacy of onabotulinumtoxinA injections for children and adolescents with chronic migraine: A systematic review and meta-analysis. Headache. 2024;64(10):1200-1216.

Maloku A, Hamadanchi A, Günther A, et al. Patent Foramen Ovale (PFO): History, Diagnosis, and Management. Rev Cardiovasc Med. 2024;25:422.

Shah AH, Horlick EM, Kass M, et al. The pathophysiology of patent foramen ovale and its related complications. Am Heart J. 2024;277:76-92.

Ji L, Wang Y, Chen Y, et al. Preliminary study on the application of percutaneous patent foramen ovale (PFO) closure in the treatment of children with PFO and severe migraine. Transl Pediatr. 2025;14(6):1181-1187.

Leighton T, VanHorne E, Parsons D. Oxygen straight to the brain: An overview of hyperbaric oxygen therapy for a variety of brain morbidities. Curr Sport Med Report. 2024;23:130-136.

Deng Z, Chen W, Jin L, et al. The neuroprotection effect of oxygen therapy: a systematic review and meta-analysis. Niger J Clin Pract. 2018;21:401-416.

Bennett MH, French C, Schnabel A, Wasiak J, Kranke P, Weibel S. Normobaric and hyperbaric oxygen therapy fort he treatment and prevention of migraine and cluster headache. Cochrane Database Syst Rev. 2015;2015(12):CD005219.

Linde K, Allais G, Brinkhaus B, et al. Acupuncture for the prevention of tension-type headache. Cochrane Database Syst Rev. 2016;2016:CD007587.

Doll E, Threlkeld B, Graff D, et al. Acupuncture in adult and pediatric headache: a narrative review. Neuropediatrics. 2019;50:346-352.

RaffagnatoA, Rossaro MP, Piretti E, et al. Acupuncture for the prevention of primary headaches in children and adolescents: A literature overview for the pediatric neurologists. Pediatr Neurol. 2025;165:22-30.

Graff DM, McDonald MJ. Auricular acupuncture for the treatment of pediatric migraines in the emergency department. Pediatr Emerg Care. 2016;34:258-262.

Tsai SL, Reynoso E, Shin DW, et al. Acupuncture as a nonpharmacologic treatment for pain in a pediatric emergency department. Pediatr Emerg Care. 2021;37:e360-e366.

Knestrick KE, Gibler RC, Reidy BL, Powers SW. Psychological interventions for pediatric headache disorders: a 202 update on research progress and needs. Curr Pain Headache Rep. 2022;26(1):85-91.

Grazzi L, Andrasik F, D’Amico D, et al. Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years. Headache. 2002;42(6):483-490.

Powers SW, Kashikar-Zuck SM, Allen JR, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomised clinical trial. JAMA. 2013;310(24):2622-2630.

Anttila P. Tension-type headache in children and adolescence. Lancet Neurol. 2006;5:268-274.

Papetti L, Spalice A, Nicita F, et al. Migraine treatment in developmental age: Guidelines update. J Headache Pain. 2010;11:267-276.

Toldo I, Rattin M, Perissinotto E, et al. Survey on treatments for primary headaches in 13 specialized juvenile Headache Centers: The first multicenter Italian study. Eur J Paediatr Neurol. 2017;21(3):507.

Moore RA, Derry S, Wiffen PJ, Straube S, Bendtsen L. Evidence for efficacy of acute treatment of episodic tension-type headache: methodological critique of randomised trials for oral treatments. Pain. 2014;155:2220-2228.

Raucci U, Boni A, Evangelisti M, et al. Lifestyle modifications to help prevent headache at a developmental age. Front Neurol. 2021;11:618375.

Palermo TM, Eccleston C, Lewandowski AS, de C Williams AC, Morley S. Randomized controlled trials of psychological therapies for management of chronic pain in children and adolescents: An updated meta-analytic review. Pain. 2010;148:387-397.

Andrasik F, Grazzi L, Usai S, Bussone G. Pharmacological treatment compared to behavioral treatment for juvenile tension-type headache: Results at two-year follow-up. Neurol Sci. 2007;28:S235-S238.

Polese D, Belli A, Esposito D, et al. Psychological disorders, adverse childhood experiences and parental psychiatric disorders in children affected by headache: A systematic review. Neurosci Biobehav Rev. 2022;140:104798.

Lee HJ, Cho S, Seo J, Schytz HW. Update on tension-type headache. Headache Pain Res. 2025;26(1):38-47.

Baglioni V, Orecchio S, Esposito D, Faedda N, Natalucci G, Guidetti V. Tension-type headache in children and adolescents. Life. 2023;13:825.